Free Trial

Beyond Air Q3 2023 Earnings Report

Beyond Air logo
$0.44 +0.02 (+5.13%)
As of 04:00 PM Eastern

Beyond Air EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.42
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Beyond Air Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Beyond Air Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Beyond Air Earnings Headlines

Insider Stock Buying Reaches US$1.60m On Beyond Air
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Beyond Air receives CE Mark for LungFit PH System
See More Beyond Air Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Beyond Air? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beyond Air and other key companies, straight to your email.

About Beyond Air

Beyond Air (NASDAQ:XAIR) operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

View Beyond Air Profile

More Earnings Resources from MarketBeat